You are here

P&T® Journal contents for September 2004


Health Care & Law
Dr. Field discusses the benefits and drawbacks of disclosing clinical trial results to the public.
Robert I. Field, JD, MPH, PhD
The authors present an illustration of an innovative Hospital Quality Incentive Payment System for improved patient care.
Mark Baumel, MD, MS, Jeff Danilo, Linda Hart, Steve Brown, MD, Timothy Zeddies, PhD, Kathleen Clark, and Joseph C. Gallo, Jr.
Dr. Goldenberg reviews the role of the FDA, safety issues regarding new medical devices, and some of the possible reasons for their failure and recall.
Marvin M. Goldenberg, PhD, RPh, MS
Continuing Education Credit
Dr. Yates discusses the use of two agents, pioglitazone and rosiglitazone, in the treatment of patients with type-2 diabetes after the removal of troglitazone from the market.
Scott W. Yates, MD, MBA


David Nash, MD, MBA, details some of the challenges involved in developing the contract language of clinical trials.
David Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, discusses ways to prevent errors involving liquid medications.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses a large-scale effort to accelerate the arrival of electronic health records for patients in the U.S.
Stephen Barlas
P&T presents the latest information about FDA approvals, drug indications, industry updates, and new devices.
Drug Forecast
The authors review risperidone (Risperdal Consta™), the first long-acting atypical antipsychotic agent.
Suzanne Thompson, PharmD, and Jose A. Rey, PharmD